Beijing Shengyong Pharmaceutical

Beijing Shengyong Pharmaceutical is a clinical-stage biotechnology company dedicated to the discovery and development of innovative small molecule drugs for metabolic and chronic diseases. Based in Beijing, the company focuses on high-potential targets such as the thyroid hormone receptor beta (THR-beta) to address unmet needs in non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, SY-001, is a highly selective THR-beta agonist currently undergoing Phase 1 clinical evaluation in both the United States and China. The company leverages a proprietary medicinal chemistry platform to optimize the safety and efficacy of its pipeline candidates. Shengyong Pharmaceutical is supported by leading healthcare investors and aims to become a leader in the metabolic disease therapeutic space.